M918T mutation in RET was identified in thyroid gland carcinoma, as a gain of function mutation, increasing the substrate binding and conferring drug resistance.268,269 Furthermore, RET A883F mutation, also a gain of function mutation, increased RET kinase activity in solid tumors of thyroid cancer.270–272. Here, RET is linked to thyroid cancer.